Nuwellis signs letter of intent to acquire Rendiatech

Nuwellis (NASDAQ:NUWE [https://seekingalpha.com/symbol/NUWE]) has signed a non-binding letter of intent [https://seekingalpha.com/pr/20204874-nuwellis-signs-letter-of-intent-to-explore-acquisition-of-rendiatech-ltd-a-real-time-fluid] to acquire Israeli-based medical device company, Rendiatech.

A 45-day due diligence period has commenced. Should both parties agree to proceed, the transaction is anticipated to close in the fourth quarter of 2025, pending final Board approval and closing conditions.

Rendiatech specializes in real-time urine flow and acute kidney injury monitoring technologies. As part of the proposed transaction, Nuwellis would add to its product portfolio Rendiatech’s Clarity RMS, an FDA-cleared critical care monitoring system that continuously measures urine flow and automatically sends data and alerts of fluctuations to medical staff in real-time.

The proposed acquisition is expected to support Nuwellis’ strategy to expand its current technology platform beyond ultrafiltration by potentially adding continuous renal health monitoring technologies.

NUWE -6.9% premarket.

MORE ON NUWELLIS

* Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4813796-nuwellis-inc-nuwe-q2-2025-earnings-call-transcript]
* Nuwellis outlines Q3 recovery and strategic shift after resolving $400,000 back order [https://seekingalpha.com/news/4485621-nuwellis-outlines-q3-recovery-and-strategic-shift-after-resolving-400000-back-order]
* Nuwellis prices public offering of stock and warrants; shares down over 37% [https://seekingalpha.com/news/4456572-nuwellis-prices-public-offering-of-stock-and-warrants-shares-down-over-37]
* Financial information for Nuwellis [https://seekingalpha.com/symbol/NUWE/income-statement]